ORPHA:79154
2-aminoadipic 2-oxoadipic aciduria
Also known as: Alpha-aminoadipic aciduria
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
36
38.6th percentile
Trials
0
Interventional, condition-specific
Researchers
320
Distinct authors in sample
Gene link
DHTKD1
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of lysine and tryptophan metabolism characterized by 2-aminoadipic and 2-oxoadipic aciduria. Patients may also present with increased urinary excretion of alpha-hydroxyadipic acid. Variable clinical presentations have been found in patients including , , mild to severe , , , and behavioral disorders (most commonly attention deficit hyperactivity disorder). However, many individuals with the biochemical are completely asymptomatic and thus the clinical significance of the condition is questionable.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008774
- MeSH:C565453
- OMIM:204750
- OMIM:245130
- UMLS:C1859817
Additional Mondo synonyms (4)
AMOXAD · Ketoadipicaciduria · alpha-aminoadipic aciduria · alpha-aminoadipic and alpha-ketoadipic aciduria
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — DHTKD1
- LiteraturePresent
36 matched papers (22 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DHTKD1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
36
36 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
36 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
22 in the last 10 years · high confidence · 38.6th percentile (publications denominator)
Phrase hits: 36 · MeSH hits: 0
Who's working on it?
320
Distinct author names in 36 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Houten SM5 papers · 2022
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 02Jordan F5 papers · 2022
Department of Chemistry, Rutgers, The State University of New Jersey, Newark, NJ 07102, USA.
Papers in Europe PMC - 03Leandro J5 papers · 2022
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 04Nemeria NS5 papers · 2022
Department of Chemistry, Rutgers, The State University of New Jersey, Newark, NJ 07102, USA.
Papers in Europe PMC - 05Zhang X4 papers · 2022
Department of Chemistry, Rutgers, The State University of New Jersey, Newark, NJ 07102, USA.
Papers in Europe PMC - 06Sanchez R3 papers · 2022
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 07Ambrus A2 papers · 2022
Department of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest H-1094, Hungary.
Papers in Europe PMC - 08DeVita RJ2 papers · 2020
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 09Dodatko T2 papers · 2020
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Papers in Europe PMC - 10Duran M2 papers · 2015Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"2-aminoadipic 2-oxoadipic aciduria" OR "Alpha-aminoadipic aciduria" OR "AMOXAD" OR "Ketoadipicaciduria" OR "alpha-aminoadipic and alpha-ketoadipic aciduria"
MeSH descriptor terms unioned into the query: Ketoadipicaciduria
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"2-aminoadipic 2-oxoadipic aciduria" OR "Alpha-aminoadipic aciduria" OR "AMOXAD" OR "Ketoadipicaciduria" OR "alpha-aminoadipic and alpha-ketoadipic aciduria" OR "DHTKD1"
Recall-expansion terms: DHTKD1
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:04:49.793Z